Ligand Pharmaceuticals Incorporated
LGNYZ News Today: Stay Updated with the Latest Ligand Pharmaceuticals Incorporated News in Real Time
Find LGNYZ news now at Meyka AI. Stay informed with the latest Ligand Pharmaceuticals Incorporated stocks updates, including price news, market analysis, and expert insights.
6255.T stock JPY 770.00 pre-market ahead of 04 Apr 2026 earnings: EPS in focus
Pre-market update on 6255.T stock at JPY 770.00 ahead of April 8 earnings; EPS and guidance in focus
PHASQ falls 99.00% to $0.000001 on 03 Apr 2026: immediate liquidity risk
PHASQ stock fell 99.00% to $0.000001 on 03 Apr 2026; Meyka AI explains drivers, liquidity, and forecast for investors
^GSPC Today April 03: Pharma 100% Tariff, Metals Duty Overhaul
Trump tariffs shake markets as pharma faces a 100% headline rate and metals duties tighten to spot prices. What this means for HK investors and the S&P 500 today.
CSCI.TO COSCIENS Biopharma (TSX) up 90.08% intraday 02 Apr 2026: catalyst, outlook
Intraday: CSCI.TO stock jumps 90.08% to C$2.30 on 02 Apr 2026; volume surge and Meyka forecast analysis
Australia stocks lower at close of trade; S&P/ASX 200 falls 1.06% amid market weakness
Australia stocks ended significantly lower at the close of trade on April 2, 2026, as the benchmark S&P/ASX 200 fell 1.06 percent to 8,579.50 points, reflecting a broad market sell‑off driven by geopolitical risk, rising oil prices, and weaker investor sentiment across major sectors. The drop marked a clear reversal from the prior session’s strong…
Aurobindo Pharma, Biocon, Glenmark Shares Plunge Over 5% as Nifty Pharma Drops 3.5%
The Indian stock market witnessed heavy selling in pharmaceutical companies as sectoral weakness dragged major stocks lower. Shares of Aurobindo Pharma, Biocon, and Glenmark Pharmaceuticals declined more than 5%, while the Nifty Pharma index dropped nearly 3.5%, emerging as one of the worst-performing sectoral indices of the session. The broad-based fall reflected global concerns, tariff…
William Blair: Market Perform for CSL (Carlisle Companies Incorporated) Mar 2026
William Blair maintained Market Perform on CSL. CSL analyst rating update March 2026
RMB23.4bn loss at Fosun (0656.HK HKSE) pre-mkt Apr 2026: watch pharma recovery
Pre-market Apr 2026: 0656.HK stock — RMB23.4bn loss, core pharma growth; Meyka AI year target HKD 4.82 (+12.58%)
BofA Unveils 10 US Stock Picks for Q2 as Market Pullback Creates Opportunities
As the US equity market experiences a mild pullback in early 2026, BofA analysts are highlighting opportunities for long‑term investors. BofA has released a new set of 10 recommended US stocks that it believes could benefit from current valuations and broader economic trends. These picks reflect strong fundamentals, sector growth potential, and positioning in future‑oriented…